文献速递慢性静脉疾病

1470nm激光联合肿胀麻醉与隐股静脉结扎倾向评分匹配比较

Endovenous Laser Ablation with 1,470-nm Diode with Tumescence Anesthesia and Saphenofemoral Ligation: Propensity Score Match Comparison.
PubMed 文献 · Ann Vasc Surg · 2019-02-13

本研究通过倾向评分匹配比较开放隐股静脉结扎(SFL)与腔内激光消融(EVLA)治疗大隐静脉反流的效果。共纳入123例患者(EVLA组59例,SFL组64例),匹配后分析74例。结果显示两种技术均安全有效,EVLA组复发率较低且生活质量感知良好,但差异无统计学意义。

要点

  • EVLA与SFL治疗大隐静脉反流均安全有效,症状改善良好。
  • 12个月时EVLA组大隐静脉再通率10.2%,SFL组腹股沟复发静脉曲张率15.6%,差异无统计学意义(P=0.369)。
  • 倾向评分匹配后手术方式与结局风险无关(OR 1.76,95%CI 0.52-6.01)。

核心结论

  • EVLA(1470nm)与SFL均安全有效,EVLA复发率较低且生活质量感知良好。
  • 肿胀麻醉效果良好,可扩展应用于开放手术结扎。

研究设计与样本

  • 连续纳入2014年起接受EVLA治疗的原发性单侧大隐静脉反流患者,另设SFL治疗系列。
  • 按治疗方式分层,采用倾向评分1:1匹配,协变量包括年龄、性别、BMI、CEAP分期、大隐静脉及隐股交界直径。
  • 共纳入123例患者(EVLA组59例,SFL组64例),匹配后分析74例(每组37例)。

主要发现

  • 12个月时SFL组腹股沟复发静脉曲张10例(15.6%),EVLA组大隐静脉再通6例(10.2%),P=0.369。
  • 额外大隐静脉复发静脉曲张36例(29.3%):开放组20例(31.2%),EVLA组16例(27.1%),P=0.615。
  • 匹配后逻辑回归显示结局风险与手术方式无关(OR 1.76,95%CI 0.52-6.01)。
  • 次要结局包括静脉血栓、色素沉着、感觉异常、术后疼痛、镇痛需求及瘀斑,出院时评估;术后1个月评估CEAP分期和生活质量。

关键数值与推荐

  • 主要结局为治疗后1年大隐静脉闭塞或腹股沟复发静脉曲张。
  • 次要结局包括静脉血栓、色素沉着、感觉异常、术后疼痛、镇痛需求、瘀斑(出院时)及CEAP分期和生活质量(术后1个月)。

临床怎么用

  • EVLA(1470nm)联合肿胀麻醉可作为大隐静脉反流的治疗选择,复发率较低且生活质量感知良好。
  • 肿胀麻醉可考虑扩展应用于开放手术结扎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study is to compare 2 groups of patients treated for great saphenous vein (GSV) reflux with open surgical saphenofemoral ligation (SFL) and endovenous laser ablation (EVLA). METHODS: Consecutive patients with primary unilateral GSV reflux undergoing EVLA treatment since 2014 were enrolled, and another series of patients treated with SFL was considered. The patients were stratified according to treatment and the results were compared using the propensity score (1:1). The covariables were age, gender, body mass index, CEAP (Clinical class, Etiology, Anatomy and Pathophysiology) staging, and GSV and saphenofemoral junction diameters. Primary outcomes were GSV occlusion or recurrent groin varicose veins at 1 year after treatment. Secondary outcomes included vein thrombosis, hyperpigmentation, paresthesia, postoperative pain, analgesic requirement, and ecchymosis assessed at discharge and CEAP stage and quality of life (QoL) assessment 1 month after surgery. RESULTS: A total of 123 patients were included in the study: 59 were treated with EVLA and 64 with SFL. At 12 months, we observed 10 recurrent groin varicose veins after SFL (15.6%) and 6 GSV recanalization after EVLA (10.2%, P = 0.369). Extra-saphenous recurrent varicose veins were observed in 36 patients (29.3%): 20 in the open group (31.2%) and 16 in EVLA group (27.1%, P = 0.615). After matching procedure 74 patients were analyzed (37 patients by group), logistic regression model showed that the risk of outcome was not associated with the surgical treatment (odds ratio 1.76, 95% confidence interval 0.52-6.01). CONCLUSIONS: Both techniques to treat saphenous impairment have demonstrated to be safe, with good results in terms of efficacy and symptomatic improvement at follow-up. EVLA with 1,470 nm seems to have lower rates of recurrence and good perceived QoL. Tumescent anesthesia is a good option with good results and may be extended to open surgical ligation.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Leopardi M, Salerno A, Dante A, et al. Endovenous Laser Ablation with 1,470-nm Diode with Tumescence Anesthesia and Saphenofemoral Ligation: Propensity Score Match Comparison. Ann Vasc Surg. 2019. PMID: 30769060. doi:10.1016/j.avsg.2018.11.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。